Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | CCKBR | P32239 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30627531 | 1.00 | ABCB11 (0.62) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10459641 | 0.97 | ABCB11 (0.59) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL7331615 | 0.96 | HRH1 (0.59) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10556510 | 0.96 | ABCB11 (0.58) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10460874 | 0.96 | ABCB11 (0.58) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| Hydrochloric Acid SCHEMBL10460868 | 0.95 | ABCB11 (0.57) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10460722 | 0.95 | KDM4E (0.58) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10459194 | 0.95 | ABCB11 (0.58) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL10461477 | 0.92 | PAX8 (0.54) | ABCB11CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL7435992 | 0.92 | HRH1 (0.54) | ABCB11CHRM2HTR1AADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2913062-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY | JAPAN INNOVATIVE THERAPEUTICS INC (JP) | 2019-05-08 | — | — | EP | claimed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | claimed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | claimed |
| US-4032642-A | SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1977-06-28 | — | — | US | claimed |
| US-3956296-A | ANTIINFLAMMATORY, SEDATIVES, TRANQUILIZERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1976-05-11 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| WO-2021225767-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-11 | — | — | WO | disclosed |
| US-10330670-B2 | Therapeutic or prophylactic agent for retinopathy of prematurity, testing method for retinopathy of prematurity, and screening method for therapeutic or prophylactic substance for retinopathy of prematurity | NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY (JP) | 2019-06-25 | — | — | US | disclosed |
| EP-2913062-B1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY AND METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY | JAPAN INNOVATIVE THERAPEUTICS INC (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-20150276718-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY, TESTING METHOD FOR RETINOPATHY OF PREMATURITY, AND SCREENING METHOD FOR THERAPEUTIC OR PROPHYLACTIC SUBSTANCE FOR RETINOPATHY OF PREMATURITY | JAPAN INNOVATIVE THERAPEUTICS, INC. (JP) | 2015-10-01 | — | — | US | disclosed |
| EP-2913062-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR RETINOPATHY OF PREMATURITY, METHOD OF TESTING FOR RETINOPATHY OF PREMATURITY, AND SCREENING METHOD FOR THERAPEUTIC OR PROPHYLACTIC SUBSTANCE FOR RETINOPATHY OF PREMATURITY | Japan Innovative Therapeutics, Inc. (JP) | 2015-09-02 | — | — | EP | disclosed |
| EP-1517706-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA Pharma AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| EP-1506016-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA Pharma AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094967-A2 | NEW COMBINATION OF REVERSIBLE PROTON PUMP INHIBITORS AND AIRWAY THERAPEUTICS FOR TREATING AIRWAY DISORDERS | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003094968-A2 | COMBINATION OF A PROTON PUMP INHIBITOR AND A RESPIRATORY AGENT FOR THE TREATMENT OF RESPIRATORY DISEASES | ALTANA PHARMA AG (DE) | 2003-11-20 | — | — | WO | disclosed |
| US-5070087-A | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-12-03 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | ABCB11 2194/4885CHRM2 2010/4885HTR1A 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.